SCHEMBL18340899

SCHEMBL18340899

CCNc1cccc(Br)c1[N+](=O)[O-]

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KAT2B Q92831 1/20 0.44
ALDH1A1 P00352 5/20 0.43
MAPT P10636 5/20 0.42
PTGER4 P35408 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
HCAR3 P49019 1/20 0.40
LMNA P02545 1/20 0.38
MEN1 O00255 1/20 0.36
USP2 O75604 1/20 0.36
CASP1 P29466 1/20 0.36
BRCA1 P38398 1/20 0.36
CASP7 P55210 1/20 0.36
KMT2A Q03164 1/20 0.36
GAA P10253 2/20 0.36
MAPK1 P28482 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
TP53 P04637 1/20 0.36
TSHR P16473 1/20 0.36
PMM2 O15305 1/20 0.35
MPI P34949 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3146630 0.88 KAT2B (0.50) KAT2BALDH1A1MAPTTDP1HCAR3
SCHEMBL17268405 0.87 KAT2B (0.49) KAT2BALDH1A1MAPTPTGER4TDP1
SCHEMBL12970295 0.84 KAT2B (0.53) KAT2BALDH1A1MAPTTDP1HCAR3
SCHEMBL16486930 0.83 KAT2B (0.52) KAT2BALDH1A1MAPTTDP1HCAR3
SCHEMBL16831412 0.81 KAT2B (0.64) KAT2BALDH1A1MAPTTDP1HCAR3
SCHEMBL31577354 0.81 ALDH1A1 (0.44) KAT2BALDH1A1MAPTTDP1HCAR3
SCHEMBL7881974 0.81 ALDH1A1 (0.44) KAT2BALDH1A1MAPTTDP1HCAR3
SCHEMBL18340832 0.81 KAT2B (0.46) KAT2BALDH1A1MAPTPTGER4TDP1
SCHEMBL18322365 0.80 KAT2B (0.44) KAT2BALDH1A1MAPTPTGER4TDP1
SCHEMBL982086 0.80 KAT2B (0.48) KAT2BALDH1A1MAPTTDP1HCAR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3313828-B1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME LLC (US) 2023-07-12 EP disclosed
US-10227331-B2 Metallo-β-lactamase inhibitors MERCK SHARP & DOHME CORP. (US) 2019-03-12 US disclosed
US-20180179190-A1 METALLO-BETA-LACTAMASE INHIBITORS Marck Sharp & Dohme Corp. (US) 2018-06-28 US disclosed
EP-3313828-A1 METALLO-BETA-LACTAMASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2018-05-02 EP disclosed
WO-2016206101-A1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-12-29 WO disclosed
WO-2016210234-A1 METALLO-BETA-LACTAMASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10227331-B2 Metallo-β-lactamase inhibitors ALPI, GAA, ZFX KAT2B 3425/4885ALDH1A1 310/4885MAPT 3705/4885
US-20180179190-A1 METALLO-BETA-LACTAMASE INHIBITORS ALPI, GAA, ZFX KAT2B 3443/4885ALDH1A1 319/4885MAPT 3748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.